[4-(4-fluorophenyl)(1,3-thiazol-2-yl)](3,4-dichlorophenyl)amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(4-fluorophenyl)(1,3-thiazol-2-yl)](3,4-dichlorophenyl)amine
• 英文别名: N-(3,4-dichlorophenyl)-4-(4-fluorophenyl)thiazol-2-amine；N-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-1,3-thiazol-2-amine
• 化学式: C₁₅H₉Cl₂FN₂S
• 分子量: 339.22
• InChiKey: XMXUAPSFOBNOQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20010044545A1

  公开（公告）日：2001-11-22

  The present invention relates to the use of aminothiazole derivatives of Formula I of as inhibitors of PAI-1, and to novel classes of aminothiazole derivatives, their synthesis and their use as inhibitors of PAI-1. It has been discovered that compounds of Formula I: 1 or a solvate, hydrate or a pharmaceutically acceptable salt thereof, wherein Y, Ar 1 , Ar 2 , R 1 , R 2 , Z, m and n are described in the specification, inhibit plasminogen activator inhibitor-1 (PAI-1). These compounds can be used in the prophylaxis or for the treatment of thrombosis, angina pectoris, cerebral infarction, myocardial infarction, pulmonary infarction, intra-atrial thrombus in atrial fibrillation, deep venous thrombus, disseminated intravascular coagulation syndrome, diabetic complications, restenosis and stroke.

  本发明涉及使用公式I的氨基噻唑衍生物作为PAI-1的抑制剂，以及新型氨基噻唑衍生物类、它们的合成和作为PAI-1抑制剂的应用。发现公式I的化合物：1或其溶剂化物、水合物或药学上可接受的盐，其中Y、Ar1、Ar2、R1、R2、Z、m和n在说明书中有所描述，能够抑制纤溶酶原激活抑制剂-1（PAI-1）。这些化合物可用于预防或治疗血栓形成、心绞痛、脑梗死、心肌梗死、肺梗死、房颤中的心房内血栓、深静脉血栓、弥散性血管内凝血综合征、糖尿病并发症、再狭窄和中风。
• Thiazole compounds and methods of use
  申请人：Zhang Suoming

  公开号：US20070004711A1

  公开（公告）日：2007-01-04

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zhang Suoming

  公开号：US20120108576A1

  公开（公告）日：2012-05-03

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• US6586453B2
  申请人：——

  公开号：US6586453B2

  公开（公告）日：2003-07-01
• US8088806B2
  申请人：——

  公开号：US8088806B2

  公开（公告）日：2012-01-03